Journal of Surgical Research
Volume 142, Issue 2 , Pages 268-274 , October 2007

Serum Protein Profiling to Identify High-Risk Neuroblastoma: Preclinical Relevance of Blood-Based Biomarkers

  • John A. Sandoval, M.D.

      Affiliations

    • Department of Surgery, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • ,
  • Katharyn E. Turner, B.A.

      Affiliations

    • Section of Pediatric Surgery, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • ,
  • Derek J. Hoelz, Ph.D.

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • ,
  • Frederick J. Rescorla, M.D.

      Affiliations

    • Department of Surgery, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • Section of Pediatric Surgery, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • ,
  • Robert J. Hickey, Ph.D.

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • ,
  • Linda H. Malkas, Ph.D.

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Indiana University, School of Medicine and Riley Hospital for Children, Indianapolis, Indiana
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Division of Hematology/Oncology, Indiana University Cancer Research Institute, 1044 West Walnut St, R4-202, Indianapolis, IN.

Received 8 January 2007

References 

  1. Brodeur GM, Castlebery RP. Neuroblastoma. In:  Pizzo PA,  Poplack DG editor. Principles and practice of pediatric oncology. 3rd ed.. Philadelphia: Lippincott; 1997;p. 761
  2. Matthay KK. Neuroblastoma. In:  Pochedly C editors. Neoplastic diseases in childhood. Chur, Switzerland: Harwood; 1994;p. 735
  3. Kaneko M, Tsuchida Y, Uchino J, et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol (Study Group of Japan for Treatment of Advanced Neuroblastoma). J Pediatr Hematol Oncol. 1999;21:190
  4. Sandoval JA, Dobrolecki LE, Huang J, et al. Neuroblastoma detection using serum proteomic profiling: A novel mining technique for cancer?. J Pediatr Surg. 2006;41:639
  5. Villanueva J, Philip J, Chaparro CA, et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res. 2005;4:1060
  6. Rowe DH, Huang J, Li J, et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg. 2000;35:977
  7. Sandoval JA, Hoelz DJ, Woodruff HA, et al. Novel peptides secreted from human neuroblastoma: Useful clinical tools?. J Pediatr Surg. 2006;41:245
  8. Mackiewicz A, Mackiewicz K. Glycoforms of serum α-1 acid glycoprotein as markers of inflammation and cancer. Glycoconj J. 1995;12:241
  9. Hashimoto S, Asao T, Takahashi J, et al. α1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer. 2004;101:2825
  10. Chawla RK, Lawson DH, Sarma PR, et al. Serum α-1 proteinase inhibitor in advanced cancer: Mass variants and functionally inert forms. Cancer Res. 1987;47:1179
  11. Daddi G, Mancini A. Increase of the α-1 antitrypsin in lung cancers. Boll Ist Sieroter Milan. 1976;55:262
  12. Tountas Y, Sparos L, Theodoropoulos C, et al. α-1 antitrypsin and cancer of the pancreas. Digestion. 1985;31:37
  13. Sukata T, Uwagawa S, Ozaki K, et al. α(2)-macroglobulin: A novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers. Am J Pathol. 2004;165:1479
  14. Ternell M, Moldawer LL, Lonnroth C, et al. Plasma protein synthesis in experimental cancer compared to paraneoplastic conditions, including monokine administration. Cancer Res. 1987;47:5825
  15. Levo Y, Wollner S, Treves AJ. Serum amyloid P-component levels in patients with malignancy. Scand J Immunol. 1986;24:147
  16. Kaneti J, Winikoff Y, Zimlichman S, et al. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res. 1984;12:239
  17. Li J, Tan C, Xiang Q, et al. Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. J Protein Chem. 2001;20:265
  18. Tan C, Li J, Wang J, et al. Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection. Proteomics. 2002;2:306
  19. Shiyan SD, Bovin NV. Carbohydrate composition and immunomodulatory activity of different glycoforms of α-1 acid glycoprotein. Glycoconj J. 1997;14:631
  20. Kawakami T, Hoshida Y, Kanai F, et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics. 2005;5:4287
  21. Ahmed N, Barker G, Oliva KT, et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 2004;91:129
  22. Bharti A, Ma PC, Maulik G, et al. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004;24:1031
  23. Smeets MB, Fontijn J, Kavelaars A, et al. The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissues. Int J Exp Pathol. 2003;84:69
  24. Ang IL, Poon TC, Lai PB, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: A glycoproteomic approach. J Proteome Res. 2006;5:2691
  25. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer. 2006;118:2803
  26. Biran H, Friedman N, Neumann L, et al. Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol. 1986;39:794
  27. Kimura M, Tomita Y, Imai T, et al. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer. 2001;92:2072
  28. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004;10:43
  29. Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid a as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84
  30. Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. Ann Intern Med. 1979;91:383
  31. Combaret V, Bergeron C, Brejon S, et al. Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett. 2005;228:91
  32. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110
  33. Francis DM, Shenton BK, Proud G, et al. Immunosuppressive plasma factors in malignant disease. Aust N Z J Surg. 1985;55:111
  34. Samak R, Edelstein R, Israel L. Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer. Cancer Immunol Immunother. 1982;13:38
  35. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997;18:428
  36. Nedelkov D, Kiernan UA, Niederkofler EE, et al. Population proteomics: The concept, attributes, and potential for cancer biomarker research. Mol Cell Proteomics. 2006;5:1811

PII: S0022-4804(07)00172-2

doi: 10.1016/j.jss.2007.03.058

Journal of Surgical Research
Volume 142, Issue 2 , Pages 268-274 , October 2007

Article Tools

* Image Usage & Resolution